Krishna Institute of Medical SciencesQ3 FY24

Krishna Institute of Medical Sciences Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹768.3P/E: 158.8Market Cap: ₹32.3K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Consolidated revenue for nine months ended Dec 2023 grew 14% YoY to INR1,874 crores.
  • Growth driven by addition of new specialties (e.g., oncology, mother and child) in Andhra and Telangana.
  • Expansion plans underway with new facilities in Bangalore, Nashik, Thane, Nagpur targeting 400+ beds by FY25.
  • Expected rise in Average Revenue Per Occupied Bed (ARPOB) by 5-7% over 2-3 years via pricing and case mix improvement.
  • Volume growth seen in inpatient (3.6% YoY) and outpatient (2.7% YoY) in Q3 FY24, with temporary Q3 dip due to festivals, elections, and cyclone effects.
  • New specialty launches expected to drive revenue growth but with some initial cost.
  • Expansion of bed capacity in existing clusters to meet demand (e.g., 125 beds to become operational in Telangana, 250+ in Andhra in next 2 quarters).
  • Greenfield projects like Nashik expected to breakeven within a year, indicating quick volume ramp-up potential.

See what Krishna Institute of Medical Sciences management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • The current debt outstanding is around INR 705 crores.
  • The company plans to raise some debt to fund its expansion projects.
  • For the Mumbai Malad facility, there is some delay in finalizing the funding plan. If no deal is finalized by the end of February 2024, KIMS will fund the project themselves starting April 2024.
  • The management remains confident about securing a partner deal for the Mumbai project within 10-15 days.
  • No explicit mention of raising equity capital was made during the call.
  • Overall, near-term fundraising plans mainly focus on raising debt to support capacity expansion and new hospital projects in locations like Nashik, Thane, Bangalore, and Mumbai.

See what Krishna Institute of Medical Sciences management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Nashik project: 300 beds with a total capex of INR 250 crores including land and building (Page 19).
  • Thane project: Planned capex INR 250 crores but this excludes land and building costs, which will add more to the total project cost (Page 19).
  • Bangalore: Two hospitals planned; one with 415 beds expected operational by Q4 FY25. Work ongoing on the second hospital with an O&M contract pending (Page 13).
  • Secunderabad: Demolition of two blocks to add a new tower with additional beds; refurbishing Sunshine Hospital with 100 dedicated rehab beds (Page 18).
  • Plan to operationalize additional beds (125 in Telangana cluster and 250-260 in Andhra cluster) within the next two quarters (Page 20).
  • Expansion focus on new geographies including Bangalore, Thane, Nashik, Nagpur with detailed groundwork and talent assessment before entry (Page 21).

Track Krishna Institute of Medical Sciences — get its next earnings analysis in your feed

How does Krishna Institute of Medical Sciences rank vs peers in Healthcare Services?

Pro feature
ThisKrishna Institute of Medical Sciences
Rev 3Mar 3

How does Krishna Institute of Medical Sciences rank in Healthcare Services?

Compare Krishna Institute of Medical Sciences against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →